T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future strategic roadmap. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at critical stages of development. Among them, two candidates are expected to advance into Phase II or Phase IIb clinical trials, with 2026 anticipated to be a pivotal year for clinical data readouts and licensing value assessments. The remaining three candidates are in the late preclinical development stage and are expected to file Investigational New Drug (IND) applications progressively within this year.

Looking ahead, the Group plans to leverage T-E Pharma as its capital and strategic integration platform, consolidating R&D achievements and clinical progress across its subsidiaries, and is targeting an application for IPO in 2026. As multiple programs reach key clinical milestones, the Group will concurrently evaluate opportunities for global licensing, strategic collaborations, and capital market initiatives, accelerating the full realization of value from its technology platforms and product portfolio.

News website link:
1. https://www.ctee.com.tw/news/20260129701200-430504
2. https://news.gbimonthly.com/tw/article/show.php?num=83378